The Advisory Committee on Vaccines and Biologicals of the Food and Drug Administration (FDA) gave the green light on Thursday to approve the emergency use of a second vaccine against COVID-19, manufactured by the Modern Pharmaceutical.
The panel of experts, the same one that last week recommended to the health authorities the emergency approval of the vaccine from the pharmaceutical company Pfizer, met throughout the day this Thursday to discuss this second immunization option, in a meeting opened and streamed by YouTube.
The vote to green light the vaccine was 20-0.
Experts agreed that its benefits outweigh the risks, when administered to people over 18 years of age.
The arrival of the second coronavirus vaccine to the United States occurs just at the time when historical numbers of infections and deaths from the virus are recorded.
On Wednesday, there were at least 232,086 new confirmed positive cases and 3,293 deaths, according to our sister network NBC News.
Moderna's vaccine against COVID-19 is 94.5% effective, according to the FDA
Dec. 15, 202000: 28
The FDA concluded two days ago that
Moderna's vaccine is "safe and effective,"
which was the first sign of approval expected to take place this Friday.
After analyzing Moderna's phase 3 clinical study, the scientists assured that the vaccine meets safety requirements and is 94.5% effective after the second dose that is placed one month after the first.
News in development ...